HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
Authors:
- Cesare SarrecchiaCSCesare Sarrecchia
- Alessandra CappelliACAlessandra Cappelli
- Pasquale AielloPAPasquale Aiello
Open Access
- 1 January 2005
- journal article
- case report
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 11 (4) , 189-191
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Occult hepatitis B virus infectionTransfusion Clinique et Biologique, 2004
- Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 2003
- Prophylaxis with Lamivudine of Hepatitis B Virus Reactivation in Chronic HbsAg Carriers with Hemato-oncological Neoplasias Treated with ChemotherapyLeukemia & Lymphoma, 2003
- Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challengeLeukemia, 2002
- Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriersBlood, 2002
- Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphomaBlood, 2002
- Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignanciesEuropean Journal of Haematology, 2001
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001
- Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factorsJournal of Medical Virology, 2000
- Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigenHepatology, 1998